| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-03-30 | Pieris (Germany) The University of Melbourne (Australia) | $AUS 564,061.50 | grant | National Health and Medical Research Council (NHMRC) (Australia) | Allergic diseases - Inflammatory diseases - Respiratory diseases | Grant |
| 2015-03-27 | Adocia (France) | €32 million | private placement | US-based specialized healthcare investors | Metabolic diseases | Private placement |
| 2015-03-25 | Cerenis Therapeutics (France) | €53.4 million | IPO | Cardiovascular diseases - Metabolic diseases - Rare diseases | IPO | |
| 2015-03-25 | Horizon Discovery (UK) | £6.2 million | grant | Department for Business, Innovation and Skills (UK) Innovate UK (UK) Birmingham City Council (UK) | Technology - Services | Grant |
| 2015-03-24 | Rigontec (Germany) | €14.25 million | series A financing round | Boehringer Ingelheim Venture Fund (Germany) Wellington Partners (UK) NRW Bank (Germany) High-Tech Gründerfonds (HTGF) (Germany) Forbion Capital Partners (The Netherlands) Sunstone Capital (Denmark) | Cancer - Oncology - Infectious diseases | Series A financing round |
| 2015-03-24 | Cellectis (France) | $ 212.3 million | IPO | IPO | ||
| 2015-03-24 | Summit Therapeutics (UK) | $ 39.3 million | IPO | Infectious diseases - Neuromuscular diseases - Rare diseases | IPO | |
| 2015-03-23 | Immunovia (Sweden) | € 4.2 million | grant | European Commission’s Horizon 2020 programme | Cancer - Oncology - Diagnostic | Grant |
| 2015-03-18 | Galena Biopharma (USA - OR) | $35.4 million | private placement | Cancer - Oncology - Hematological diseases | Private placement | |
| 2015-03-17 | Alize Pharma (France) | €1.8 million | financing round | Octalfa (France) Sham Innovation Santé (France) Rhône-Alpes Création (France) Crédit Agricole Création (France) CEMA (France) TAB Consulting (France) | Bone diseases | Financing round |
| 2015-03-13 | Macrophage Therapeutics (USA - OH) | $2.5 million | financing round | Cancer - Oncology - Immunological diseases - Autoimmune diseases - Cardiovascular diseases | Financing round | |
| 2015-03-12 | Depomed (USA - CA) | $575 million | loan | Deerfield (USA - NY) Pharmakon (USA) | Loan | |
| 2015-03-11 | BiolineRx (Israel) | $28.75 million | private placement | Private placement | ||
| 2015-03-10 | The Lead Discovery Center (LDC) (Germany) | €1 million | grant | Max Planck Foundation (Germany) Dr Helmut Storz Foundation (Germany) | Cancer - Inflammatory diseases | Grant |
| 2015-03-10 | AmpliPhi BioSciences (USA - VA) | $13 million | private placement | Infectious diseases | Private placement | |
| 2015-03-10 | Effimune (France) | € 1 million | financing round | undisclosed existing Effimune investors | Autoimmune diseases - Immunological diseases - Transplantation | Financing round |
| 2015-03-10 | Delphi Genetics (Belgium) | € 1 million | capital increase | Sambrinvest (Belgium) Invest4 DelphiG2 (Belgium), François Blondel and Dr. Philippe Janssens de Varebeke, the two managing directors of the company, Mr. Michel Milinkovitch and ULB (Université Libre de Bruxelles) through its fund Theodorus (Belgium) | Technology - Services | Capital increase |
| 2015-03-06 | Nicox (France) | €27 million | capital increase | Capital increase | ||
| 2015-03-06 | Horizon Pharma (Ireland) | $386.5 million | private placement | Private placement | ||
| 2015-03-05 | Genenta Science (Italy) | € 10 million | series A financing round | Banca Esperia (Italy) Mediolanum (Italy) private investors | Cancer - Oncology - Rare diseases | Series A financing round |
